Comparative effectiveness research - a proposal for a new NHMRC funding stream

Medical Journal of Australia

Volumn 196, Issue 1, 2012, Pages 22-23

  Zalcberg, John R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; CANCER RADIOTHERAPY; CLINICAL RESEARCH; COMPARATIVE EFFECTIVENESS; COST CONTROL; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH ECONOMICS; HEALTH INSURANCE; POSTOPERATIVE CARE; STOMACH CANCER;

AUSTRALIA; COMPARATIVE EFFECTIVENESS RESEARCH; FEDERAL GOVERNMENT; FINANCING, GOVERNMENT; HUMANS;

EID: 84857869260     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja11.10036     Document Type: Article

References (11)

1. National Health and Medical Research Council. Clinical Practice Guidelines Portal. http://www.clinicalguidelines.gov.au (accessed Nov 2010).
2. The Cochrane Collaboration. Cochrane summaries. http://www2.cochrane.org/reviews/index.htm (accessed Nov 2010).
3. National Health and Medical Research Council. NHMRC standards and procedures for externally developed guidelines. 2007. http://www. nhmrc.gov.au/_files_nhmrc/file/publications/synopses/nh56.pdf (accessed Nov 2011).
4. VanLare JM, Conway PH, Sox HC. Five next steps for a new national program for comparative-effectiveness research. N Engl J Med 2010; 362: 970-973.
5. National Health and Medical Research Council. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. 2005. http://www.nhmrc.gov.au/publications/synopses/cp106/cp106syn.htm (accessed Nov 2011).
6. Australian New Zealand Clinical Trial Registry. Short Course Oncology Therapy (SCOT). A study of post operative chemotherapy for 12 weeks versus 24 weeks with oxaliplatin/Fluorouracil (5FU) to establish disease free survival outcomes in locally advanced colon cancer. http://www.anzctr.org.au/ACTRN12609000662268.aspx (accessed Apr 2011).
7. ClinicalTrials. gov. Combination chemotherapy for 3 months or 6 months in treating patients with stage III colon cancer. http://www.clinicaltrials.gov/ct2/show/NCT00958737 (accessed Apr 2011).
8. MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
9. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
10. Australian New Zealand Clinical Trial Registry. TOP GEAR: Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma. A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer. http://www.anzctr.org.au/ACTRN12609000035224.aspx (accessed Apr 2011).
11. Institute of Medicine. Initial national priorities for comparative effectiveness research. Washington DC: National Academies Press, 2009.